KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and Safety of Triple Fixed Dose Combination of Dapagliflozin + Sitagliptin + Metformin IR in Indian Patients with Type 2 Diabetes Mellitus: A Randomized, Phase 3 Study in Comparison with Dual FDC Sitagliptin + Metformin IR.

Mahendra Pal Singh, Sandeep Gupta, Manish Singh, C Ambrish, Prakash Kurmi, Dinesh Kumar Gangwani, J Naganna, Ravikumar Sethuraman, Vrindavani Dhumal, Sapan Behera, Piyush M Patel, Dipak M Patil, Lalit K Lakhwani, Pravin S Ghadge, Suyog C Mehta, Sadhna J Joglekar

Adv Ther 42(10) 5187-5201

PMID40828352
PMCIDPMC12474733
DOI10.1007/s12325-025-03323-3
发表日期2025-08-19
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other。
摘要

摘要

INTRODUCTION: This study aims to evaluate the efficacy and safety of a triple fixed-dose combination (FDC) of dapagliflozin, sitagliptin, and immediate-release metformin (DAPA + SITA + MET IR) compared to dual FDCs in patients with type 2 diabetes mellitus (T2DM). METHODS: This Phase 3, randomized, open-label study included eligible patients with T2DM who were randomly assigned in a 1:1 ratio to receive either a triple FDC of DAPA + SITA + MET IR (5 + 50 + 500/1000 mg) or a dual FDC of sitagliptin and MET IR (SITA + MET IR; 50 + 500/1000 mg), administered twice daily for 16 weeks. The primary endpoint was the mean change in glycated haemoglobin (HbA1c) from baseline to Week 16. RESULTS: The mean baseline HbA1c was ~ 9% in both arms. Adjusted mean reduction in HbA1c from baseline to Week 16 was significantly greater in triple FDC of DAPA + SITA + MET IR (- 2.08%) versus dual FDC of SITA + MET IR (- 1.38%) P < 0.0001. A significantly greater reduction in HbA1c was observed with triple FDC compared to the dual FDC at Week 12 (P < 0.0001). At Week 16, a significantly higher proportion of patients achieved HbA1c < 7% with triple FDC than with dual FDC (48.9% versus 31.1%; P = 0.0029). Both treatments were well tolerated. CONCLUSION: Triple FDC of DAPA + SITA + MET IR demonstrated superior efficacy in achieving glycaemic control in patients with T2DM compared to dual FDC. There were no major safety concerns. CLINICAL TRIAL REGISTRATION NUMBER: CTRI/2022/04/041817.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Patient disposition. BID twice daily, DAPA dapagliflozin, FDC fixed dose combination, IR immediate release, MET metformin, SITA sitagliptin
非 KM Figure
Fig. 2Fig. 2 Mean change in HbA1c from baseline at Week 12 and Week 16
非 KM Figure
Fig. 3Fig. 3 Proportion of patients who achieved HbA1c < 7% (53 mmol/mol) at Week 12 and Week 16
非 KM Figure